In Q1'26, CVS's Pharmacy segment generated $56.9B in revenue, marking a decline from the $61.7B peak in Q4'25 but remaining the largest contributor overall. The Front Store segment contributed $5.3B, showing stability after a slight uptick in the prior quarter, while Premiums added $33.8B, reflecting a minor dip from Q4'25's $34.0B. Net investment income reached $574M, and Other revenue stood at $3.9B, both exhibiting modest growth from the previous period. From Q2'23 to Q1'26, CVS's total revenue trended upward overall, growing from approximately $88.5B to $100.5B, driven primarily by the expanding Premiums segment, which surged from $25.1B to $33.8B due to consistent quarterly gains starting in Q1'24. The Pharmacy segment displayed volatility with a notable dip to $48.4B in Q1'24 before recovering to new highs, while Front Store remained relatively flat around $5.3B-$5.9B, and Other revenue steadily increased from $2.8B to $3.9B. Net investment income showed the most fluctuation, rising from $274M to $755M by Q4'24 before stabilizing near $600M, underscoring Pharmacy and Premiums as dominant drivers of the company's revenue growth.